Previous 10 | Next 10 |
BioMarin Pharmaceutical (BMRN) announces that the U.S. FDA granted Regenerative Medicine Advanced Therapy ((RMAT)) designation to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A.RMAT is an expedited program intended to facilitat...
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A RMAT Designation Granted by FDA During Bleeding Disorders Awareness Month PR Newswire SAN RAFAEL, C...
BioMarin Pharmaceutical Inc. (BMRN) has completed enrollment in its phase 2 study examining vosoritide, a once-daily injection for children with achondroplasia, the most common form of disproportionate short stature in humans.The study will last 52 weeks and include approximately 70 infants a...
BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia Topline data expected to be available in mid-2022 PR Newswire SAN RAFAEL, Calif. , March 3, 2021 /PRNewswire/ -- BioMarin Ph...
BioMarin Pharmaceutical (BMRN) rose 3.3% on "vague" speculation of potential takeover interest.BioMarin may be a takeover candidate for an unidentified company, according to a Betaville "uncooked" alert that traders were citing for the move. For further details see: BioMarin g...
BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Inve...
Image source: The Motley Fool. Biomarin Pharmaceutical Inc (NASDAQ: BMRN) Q4 2020 Earnings Call Feb 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transc...
BioMarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Traci McCarty – Vice President of Investor Relations J.J. Bienaime – Chairman and Chief Executive Officer Jeff Ajer – Executive Vice President and Chief C...
BioMarin Pharmaceutical (BMRN): Q4 GAAP EPS of $0.12 beats by $0.29.Revenue of $452.1M (-0.5% Y/Y) beats by $11.96M.As of December 31, 2020, BioMarin had cash, cash equivalents and investments totaling $1.35B.Press Release For further details see: BioMarin Pharmaceutical EPS beats ...
BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates - Full-year 2020 Total Revenues Increased 9% to $1.86 billion - Company Dose-escalates in PHEarless, a Phase 1/2 Study with BMN 307 Gene Therapy for the Treatment of Phenylket...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
U.S. Food and Drug Administration Approves BioMarin's BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease PR Newswire Now Approved for Children of All Ages with CLN2 Batten Disease, Regardless of Whether They Yet Show Symptoms SAN RAFAEL, C...
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...